# US 2026/0083751 A1 · Allosteric modulators of androgen receptor coactivator recruitment for crpc therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083751 A1
- Document ID: US20260083751A1
- Status: Published application
- Kind: A1
- Application number: 19/108,095
- Filed: 2023-08-30
- Published: 2026-03-26
- Earliest claimed: 2022-08-31
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh – Of the Commonwealth System of Higher Education
- Inventors: Paul A. Johnston; Andrew P. Hinck; Carlos J. Camacho; Peter Wipf; Zhou Wang; Lee A. McDermott
- Web page: https://patentgrep.com/patent/US20260083751A1

## CPC

- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Small molecule allosteric modulators of androgen receptor are disclosed. The compounds may inhibit androgen receptor coactivator recruitment, such as by preventing formation of protein-protein interaction (PPI) complexes and/or disrupting PPI complexes. A method of treating prostate cancer, such as castration-resistant prostate cancer, includes administering a small molecule allosteric modulator of androgen receptor.

## Claims

### Claim 1

A method of modulating androgen receptor-mediated activity, comprising:
contacting androgen receptor with an effective amount of a compound, wherein the compound is a hydrobenzo-oxazepine, a thiadiazol-5-piperidine carboxamide, a fluorophenyl-methyl-indole, a phenyl-methyl-indole, a heteroaliphatic- or heteroaryl-substituted methyl-indole, or any combination thereof, thereby inhibiting androgen receptor-coactivator (AR-CoA) protein-protein interaction (PPI) complexes, inhibiting prostate specific antigen (PSA) expression in prostate epithelial cells and/or prostate cancer cells, inhibiting PSA secretion by prostate epithelial cells and/or prostate cancer cells, inhibiting AR-mediated PSA promoter-driven transcription in prostate cancer cells, inhibiting androgen receptor splice variant 7 (AR-V7)-mediated PSA promoter driven transcription in prostate cancer cells, inhibiting ubiquitin conjugating enzyme E2 C (UBE2C) promoter-driven transcription in prostate cancer cells, inhibiting growth of prostate cancer cells, or any combination thereof,
wherein the compound has a structure according to any one of formulas I-III:
wherein
R1 is aryl or heteroaryl;
R2 is a heterocycle;
R3 is H;
X1 is S, O, or N;
R4 is —X2—Ra or halo, where X2 is CH2, S, or O, and Ra is aryl or heteroaryl;
R5 is aliphatic or a heterocycle;
R6 is —CH2N(H)Y(CH2)m—Rb, H, halo, or alkyl, where Y is C(O) or S(O)2, Rb is a heterocycle or —N(H)Y(CH2)mCH3, and each m independently is 0, 1, 2, or 3;
R7 is aryl, heteroaryl, H, or alkyl:
R8 is alkyl, aryl, a heterocycle, or H; and
R9 is H, alkyl, or —CH2N(H)Y(CH2)m—R,
wherein at least one of R6 and R9 is not H,
at least one of R7 and R1 is not H, and
one of R6-R9 is —CH3.

### Claim 2

(canceled)

### Claim 3 (depends on 21)

The method of claim 21, wherein:
(i) R1 is phenyl or thiophenyl and R2 is thiazolyl or pyrimidinyl; or
(ii) Ra is phenyl, imidazolyl, or pyrrolidinyl; or
(iii) Rb is diazolyl, pyrimidinyl, pyridinyl,
or —N(H)C(O)CH3; or
(iv) R7 is
where X is halo; or
(v) R8 is —CH3,
where n is 1 or 2, and each Rc independently is halo, —ORd, —C(O)NHRd, or aminoalkyl, where each Rd independently is H or C1-C5 alkyl; or
(vi) any combination of two or more of (i)-(v).

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound has a structure according to formula III where:
when R6 is H and R9 is methyl, then R7 is H and R8 is aryl or heteroaryl; or
when R6 is aryl and R9 is H, then R7 is aryl and R8 is methyl; or
when R6 is alkyl and R9 is H, then R7 is H and R8 is methyl; or
when R6 is halo and R9 is methyl, then R7 and R8 are not H.

### Claim 5 (depends on 1)

The method of claim 1, wherein:
(i) the compound has a structure according to formula I
wherein
R1 is
R2 is
and R3 is H; or
(ii) the compound has a structure according to formula II
wherein
X1 is S, R5 is —CH3, R4 is —S—Ra, —CH2—Ra, or F, and Ra is
or
(iii) the compound has a structure according to formula III
wherein
R6 is —CH2N(H)C(O)(CH2)m—Rb, H, F, or —CH3, where m is 0, 1, or 2, and Rb is
R7 is
where X is halo, or R7 is H or —CH2CH3,
R8 is —CH3
where n is 1 or 2, and each Rc independently is halo, —ORd, —C(O)NHRd, or aminoalkyl, where each Rd independently is H or C1-C3 alkyl, and
R9 is H, —CH3, or —CH2N(H)C(O)(CH2)m—Rb, where m is 3, and Rb is

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound has a structure according to formula IIIA, IIIB, or IIIC:
where
R6 is —CH2N(H)Y(CH2)m—Rb;
Y is CO or S(O)2;
Rb is a heterocycle or —N(H)C(O)(CH2)mCH3;
R7 is aryl or heteroaryl; and
R8 is aryl or a heterocycle.

### Claim 7 (depends on 6)

The method of claim 6, wherein:
(i) the compound has a structure according to formula IIIA, where R7 is fluorophenyl, H, or —CH2CH3, and R6
or
(ii) the compound has a structure according to formula IIIB or IIIC, where R8 is

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound is:
or any combination thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is:
or any combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein inhibiting AR-CoA PPI complexes comprises:
(i) reducing formation of AR-CoA PPI complexes; or
(ii) disrupting formed AR-CoA PPI complexes; or
(iii) both (i) and (ii).

### Claim 11 (depends on 1)

The method of claim 1, wherein the CoA comprises transcriptional intermediary factor 2 (TIF2), steroid receptor coactivator (SRC1), or a combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein contacting is performed in vivo by administering the effective amount of the compound to a subject.

### Claim 13

(canceled)

### Claim 14

A method for treating prostate cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound, wherein the compound is a hydrobenzo-oxazepine, a thiadiazol-5-piperidine carboxamide, a fluorophenyl-methyl-indole, a phenyl-methyl-indole, a heteroaliphatic- or heteroaryl-substituted methyl-indole, or any combination thereof, the compound having a structure according to any one of formulas I-III:
wherein
R1 is aryl or heteroaryl;
R2 is a heterocycle;
R3 is H;
X is S, O, or N;
R4 is —X2—Ra or halo, where X2 is CH2, S, or O, and Ra is aryl or heteroaryl;
R5 is aliphatic or a heterocycle;
R6 is —CH2N(H)Y(CH2)m—Rb, H, halo, or alkyl, where Y is C(O) or S(O)2, Rb is a heterocycle or —N(H)Y(CH2)mCH3, and each m independently is 0, 1, 2, or 3;
R7 is aryl, heteroaryl, H, or alkyl;
R8 is alkyl, aryl, a heterocycle, or H; and
R9 is H, alkyl, or —CH2N(H)Y(CH2)m—Rb,
wherein at least one of R6 and R9 is not H,
at least one of R7 and R1 is not H, and
one of R6-R9 is —CH3.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method of claim 14, wherein:
(i) R1 is phenyl or thiophenyl and R2 is thiazolyl or pyrimidinyl; or
(ii) Ra is phenyl, imidazolyl, or pyrrolidinyl; or
(iii) Rb is diazolyl, pyrimidinyl, pyridinyl,
or —N(H)C(O)CH3; or
(iv) R7 is
where X is halo; or
(v) R1 is —CH3,
where n is 1 or 2, and each Rc independently is halo, —ORd, —C(O)NHRd, or aminoalkyl, where each Rd independently is H or C1-C5 alkyl; or
(vi) any combination of two or more of (i)-(v).

### Claim 17 (depends on 14)

The method of claim 14, wherein:
when R6 is H and R9 is methyl, then R7 is H and R8 is aryl or heteroaryl; or
when R6 is aryl and R9 is H, then R7 is aryl and R8 is methyl; or
when R6 is alkyl and R9 is H, then R7 is H and R8 is methyl; or
when R6 is halo and R9 is methyl, then R7 and R8 are not H.

### Claim 18 (depends on 14)

The method of claim 14, wherein:
(i) the compound has a structure according to formula I
wherein
R1 is
R2 is
and R3 is H; or
(ii) the compound has a structure according to formula II
wherein
X1 is S, R5 is —CH3, R4 is —S—Ra, —CH2—Ra, or F, and Ra is
or
(iii) the compound has a structure according to formula III
wherein
R6 is —CH2N(H)C(O)(CH2)m—Rb, H, F, or —CH3, where m is 0, 1, or 2, and Rb is
R7 is
where X is halo, or R7 is H or —CH2CH3,
R8 is —CH3
where n is 1 or 2, and each Rc independently is halo, —ORd, —C(O)NHRd, or aminoalkyl, where each Rd independently is H or C1-C3 alkyl, and
R9 is H, —CH3, or —CH2N(H)C(O)(CH2)m—Rb, where m is 3, and Rb is

### Claim 19 (depends on 14)

The method of claim 14, wherein the compound has a structure according to formula IIIA, IIIB, or IIIC:
where
R6 is —CH2N(H)Y(CH2)m—Rb;
Y is CO or S(O)2;
Rb is a heterocycle or —N(H)C(O)(CH2)mCH3;
R7 is aryl or heteroaryl; and
R8 is aryl or a heterocycle.

### Claim 20 (depends on 19)

The method of claim 19, wherein:
(i) the compound has a structure according to formula IIIA, where R7 is fluorophenyl, H, or —CH2CH3, and R6 is
or
(ii) the compound has a structure according to formula IIIB or IIIC, where R8 is

### Claim 21 (depends on 14)

The method of claim 14, wherein compound is:
or any combination thereof.

### Claim 22 (depends on 14)

The method of claim 14, wherein the compound is:
or any combination thereof.

### Claim 23 (depends on 14)

The method of claim 14, wherein the prostate cancer is castration-resistant prostate cancer.

### Claim 24

(canceled)
